We are monitoring the impact of COVID-19 on Plasma Fractionation Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2719
Share on
Share on

Global Plasma Fractionation Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product, Application, End-Users and Region – Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2719
Pages: 175

Global Plasma Fractionation Market Size (2021 to 2026)

As per our report, the global plasma fractionation market size estimated to be growing at a CAGR of 7.2% during the forecast period. This market is expected to worth USD 33.83 billion by 2026 and USD 23.89 billion in 2021.

Plasma is the liquid portion of blood. It consists of red cells, white cells, and platelets suspended in it and contains thousands of distinct proteins and other substances like electrolytes, minerals, hormones, etc., necessary for the human body's normal function. Plasma helps in maintaining blood pressure and body temperature regulation.

MARKET DRIVERS:

Inclined to a variety of rare diseases that require the use of plasma derivatives is expected to drive the global plasma fractionation market growth.

A rare disease, according to NORD, is a disease or condition that affects less than 200,000 Americans. More than 7,000 rare diseases affect more than 30 million Americans collectively. This figure represents the prevalence rate of selected rare diseases in businesses worldwide in 2017. In that year, the global prevalence of multiple sclerosis was 90 per 100,000 people. Rare diseases account for 35% of all deaths in the first year of life. Plasma-derived products are among the safest biological therapies available; they are efficiently and strictly controlled in all aspects of their clinical use and supply chain in developed countries.

Y-O-Y growth in the prevalence of respiratory diseases across the world is another significant factor boosting the global plasma fractionation market growth.

Respiratory disorders such as asthma, COPD, and new acute Coronavirus disease. According to NIH, Plasma from COVID-19-recovered donors may produce antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may help suppress the virus and alter the inflammatory response. More than 70,000 patients in the United States have received COVID-19 convalescent plasma through the Mayo Clinic's Expanded Access Program (EAP), which was created to provide widespread access to investigational convalescent plasma.

The growing aging population with related blood-related ailments is also set to drive the global plasma fraction market growth.

Globally, the population is aging at an alarming pace in emerging countries such as India, China, and Japan, etc. According to WHO, people are living longer lives all over the world—between 2015 and 2050, the proportion of the world's population over 60 years old would nearly double from 12% to 22%. By 2050, low- and middle-income countries will house 80 percent of the elderly. France had nearly 150 years to adjust to a 10% increase in the proportion of the population over 60 years old.

Y-O-Y growing prevalence of Hemoglobin disorders such as sickle cell disease and thalassemia are expected to accelerate the global plasma fractionation market.

Hemoglobinopathies are the most common genetically inherited disorders. According to the World Health Organization (WHO), roughly 5% of the world's population is a carrier of hereditary hemoglobin (Hb) disorders. About 42 million people are carriers per year, and over 12,000 babies are born with a major and clinically meaningful hemoglobinopathy. Thalassemia is one of the most lethal diseases on the planet. It is a hereditary blood condition affecting approximately 100,000 Indian patients.

Increasing usage of immunoglobulins in different areas is a significant factor driving the global plasma fractionation market.

Factors such as increasing incidence of immune and bleeding disorders, growing prevalence of Alpha-1 Antitrypsin deficiency, and the increasing use of immunoglobulins, which are antibodies, are propelling the global plasma fractionation market. Additionally, the emergence of novel and innovative products to treat immunological deficiencies, inherited metabolic disorders, and trauma and the rising number of FDA approvals provide lucrative opportunities for the growth of plasma fractionation globally.

MARKET RESTRAINTS:

Increasing use of recombinant proteins and products serving as a replacement for plasma products and the risk factors associated with them, escalating prices of plasma derivatives, unfavorable reimbursement policies, increased use in prophylactic therapies are likely to restrain the growth of the global plasma fractionation market. Regulatory authorities strictly govern plasma products since they are made from entire blood. Stringent regulations governing the manufacturing plant, the source of whole blood, and the isolation procedure, among other things, could limit the market's expansion. Such strict policies will affect the product's production and processing time and the market's growth in the coming years.

Furthermore, the shortage of plasma protein products is caused due to the high cost of imported products, and a lack of domestic industrial fractionation capability, and a scarcity of high-quality plasma for fractionation in the local market has hampered the growth of the plasma fractionation market. Limited reimbursements, the high cost of plasma products, and the introduction of recombinant alternatives are impeding the growth of the market.

Impact of COVID-19 on the global plasma fractionation market:

The COVID-19 pandemic is expected to drive significant growth in the global plasma fractionation market. Some countries are working with plasma fractionation techniques to discover new cures and diagnostic methodologies for the novel coronavirus. The use of convalescent plasma as a treatment for COVID-19 positive patients may be a viable option. Plasma is extracted from a previously infected person's blood and then given to an actual patient. As a result of the plasma containing vital antibodies to combat the infection, the patient receives passive immunization. Octapharma, a major pharmaceutical company, is putting its knowledge to use in the search for new COVID-19 drugs. In order to improve a possible plasma-derived hyperimmune immunoglobulin treatment, it is working with leading plasma fractionation players. The alliance is looking at developing an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin. Patients with serious COVID-19 symptoms can benefit from the treatment. The company gathers convalescent plasma to help fund preclinical and clinical research on whether the anti-SARS-CoV-2 hyperimmune immunoglobulin is useful in treating COVID-19. The spread of the COVID-19 pandemic has also resulted in a reduction in the number of blood donors and plasma collections in certain countries, which has hampered the economy by causing a shortfall in raw material availability.

The COVID-19 pandemic has serious consequences for blood transfusion. According to the NIH COVID-19 Care Guidelines panel, there is insufficient evidence to recommend either for or against the use of monoclonal antibodies for the treatment of outpatients with mild to moderate COVID. To maximize revenue during the pandemic, players in the plasma fractionation industry are increasing their investments in potential immunoglobulin covid-19 vaccine production applications. In 2020, several leading biopharmaceutical firms joined forces to find therapeutic alternatives to the current global pandemic. Although there is little known about plasma-derived therapies in general, the COVID-19 pandemic has shed light on this form of therapy and highlighted its wider applications in everyday medicine. The importance of this field of pharmaceutical medicine and healthcare became clear as its understanding of the novel coronavirus increased. In response to the pandemic, the major global players in plasma-derived medicinal products, formed the CoVIg-19 Plasma Alliance to accelerate the production of investigational hyperimmune immunoglobulin therapy for the treatment of COVID-19. Convalescent plasma has been commonly used to treat coronavirus disease 2019 (Covid-19), It is unclear if convalescent plasma with high antibody levels, as opposed to low antibody levels, is associated with a lower risk of death.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Analysed

By Product, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global plasma fractionation market has been segmented and sub-segmented based on the product, application, end-user, and region.

Plasma Fractionation Market – By Product:

  • Albumin
  • Immunoglobulin
  • Factor VIII
  • Protease Inhibitors

The immunoglobulin segment is expected to dominate the global plasma fractionation market by contributing a significant share based on the product. Factors such as the increasing focus of immunology research and the growing adoption of immunoglobulin in primary and secondary immune deficiencies, inflammatory diseases, and autoimmune diseases are helping this segment experience to accumulate significantly during the forecast period.

Plasma Fractionation Market – By Application:

  • Neurology
  • Hematology
  • Rheumatology
  • Pulmonology
  • Immunology

Based on the application, the neurology segment dominates the plasma fractionation market by contributing a significant share and is expected to be the rapidly growing segment due to increasing demand for plasma fractionation products for the treatment and improving plasma fractionation applications products in the neurology field.

Plasma Fractionation Market – By End-user:

  • Hospital
  • Clinical Laboratories

Plasma Fractionation Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

As of 2019, North America leads the global market, with the U.S. accounting for a significant share. The presence of a high number of registered hemophilic patients and increasing the use of immunoglobulins in neurologic disorders are much supporting the market to grow in this region. Europe comes in second in terms of market share due to rising awareness about blood-related diseases and the swift availability of treatment in terms of plasma fractionation.

However, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period, majorly because of the presence of more significant elderly population numbers leading to a higher incidence of blood disorders.

KEY MARKET PARTICIPANTS:

Some of the notable companies playing a leading role in the global plasma fractionation market profiled in this report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).

KEY HAPPENINGS IN THIS MARKET:

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product                        

                                5.1.1 Introduction           

                                5.1.2 Fractionation Process         

                                5.1.3 Immunoglobulin   

                                5.1.4 Coagulation Factor Concentrates  

                                5.1.5 Albumin   

                                5.1.6 Protease Inhibitors              

                                5.1.7  Y-o-Y Growth Analysis, By Product              

                                5.1.8  Market Attractiveness Analysis, By Product            

                                5.1.9  Market Share Analysis, By Product              

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Neurology               

                                5.2.3 Immunology           

                                5.2.4 Hematology            

                                5.2.5 Critical Care             

                                5.2.6 Pulmonology          

                                5.2.7 Hemato-Oncology               

                                5.2.8 Rheumatology       

                                5.2.9 Other Application 

                                5.2.10 Y-o-Y Growth Analysis, By Application      

                                5.2.11 Market Attractiveness Analysis, By Application    

                                5.2.12 Market Share Analysis, By Application      

                5.3 End User                      

                                5.4.1 Introduction           

                                5.4.2 Hospitals  

                                5.4.3 Clinical Laboratories            

                                5.4.4 Academic Institutes            

                                5.4.5 Y-o-Y Growth Analysis, By End User             

                                5.4.6  Market Attractiveness Analysis, By End User          

                                5.4.7  Market Share Analysis, By End User            

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Application

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Application

                                                6.1.4.4 By End User

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Application

                                                6.1.5.4 By End User

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Baxalta Incorporated                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 CSL Ltd.                        

                8.3 Grifols S.A                   

                8.4 Octapharma AG                        

                8.5 Kedrion S.p.A                            

                8.6 Bio Products Laboratory                        

                8.7 Sanquin                        

                8.8 China Biologic Products, Inc.                

                8.9 Biotest AG                  

                8.10 Laboratoire Français du Fractionnement et des Biotechnologies                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Plasma Fractionation Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  3. Global Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Albumin Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  9. Global Neurology Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Immunology Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Hematology Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  15. Global Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  16. Global Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  17. Global Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  18. Global Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  19. Global Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  20. Global Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  22. North America Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Albumin Market, By Region, From 2021 to 2026 (USD Million)
  25. North America Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  28. North America Neurology Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Immunology Market, By Region, From 2021 to 2026 (USD Million)
  30. North America Hematology Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  32. North America Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  33. North America Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  34. North America Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  35. North America Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  36. North America Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  37. North America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  38. North America Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  39. North America Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  40. United States Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  41. United States Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  42. United States Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  43. Canada Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  44. Canada Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  45. Canada Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  46. Europe Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  47. Europe Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  48. Europe Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  49. Europe Albumin Market, By Region, From 2021 to 2026 (USD Million)
  50. Europe Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  51. Europe Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  52. Europe Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  53. Europe Neurology Market, By Region, From 2021 to 2026 (USD Million)
  54. Europe Immunology Market, By Region, From 2021 to 2026 (USD Million)
  55. Europe Hematology Market, By Region, From 2021 to 2026 (USD Million)
  56. Europe Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  57. Europe Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  58. Europe Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  59. Europe Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  60. Europe Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  61. Europe Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  62. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  63. Europe Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  64. Europe Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  65. U.K. Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  66. U.K. Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  67. U.K. Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  68. Germany Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  69. Germany Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  70. Germany Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  71. France Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  72. France Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  73. France Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  74. Italy Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  75. Italy Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  76. Italy Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  77. Spain Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  78. Spain Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  79. Spain Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  80. Asia-Pacific Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  81. Asia-Pacific Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  82. Asia-Pacific Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  83. Asia-Pacific Albumin Market, By Region, From 2021 to 2026 (USD Million)
  84. Asia-Pacific Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  85. Asia-Pacific Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  86. Asia-Pacific Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  87. Asia-Pacific Neurology Market, By Region, From 2021 to 2026 (USD Million)
  88. Asia-Pacific Immunology Market, By Region, From 2021 to 2026 (USD Million)
  89. Asia-Pacific Hematology Market, By Region, From 2021 to 2026 (USD Million)
  90. Asia-Pacific Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  91. Asia-Pacific Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  92. Asia-Pacific Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  93. Asia-Pacific Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  94. Asia-Pacific Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  95. Asia-Pacific Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  96. Asia-Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  97. Asia-Pacific Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  98. Asia-Pacific Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  99. Japan Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  100. Japan Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  101. Japan Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  102. China Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  103. China Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  104. China Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  105. India Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  106. India Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  107. India Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  108. Australia Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  109. Australia Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  110. Australia Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  111. South Korea Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  112. South Korea Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  113. South Korea Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  114. Latin America Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  115. Latin America Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  116. Latin America Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  117. Latin America Albumin Market, By Region, From 2021 to 2026 (USD Million)
  118. Latin America Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  119. Latin America Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  120. Latin America Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  121. Latin America Neurology Market, By Region, From 2021 to 2026 (USD Million)
  122. Latin America Immunology Market, By Region, From 2021 to 2026 (USD Million)
  123. Latin America Hematology Market, By Region, From 2021 to 2026 (USD Million)
  124. Latin America Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  125. Latin America Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  126. Latin America Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  127. Latin America Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  128. Latin America Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  129. Latin America Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  130. Latin America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  131. Latin America Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  132. Latin America Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  133. Brazil Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  134. Brazil Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  135. Brazil Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  136. Argentina Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  137. Argentina Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  138. Argentina Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  139. Mexico Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  140. Mexico Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  141. Mexico Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  142. Rest of Latin America Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  143. Rest of Latin America Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  144. Rest of Latin America Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  145. Middle East & Africa Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  146. Middle East & Africa Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  147. Middle East & Africa Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  148. Middle East & Africa Albumin Market, By Region, From 2021 to 2026 (USD Million)
  149. Middle East & Africa Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  150. Middle East & Africa Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  151. Middle East & Africa Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  152. Middle East & Africa Neurology Market, By Region, From 2021 to 2026 (USD Million)
  153. Middle East & Africa Immunology Market, By Region, From 2021 to 2026 (USD Million)
  154. Middle East & Africa Hematology Market, By Region, From 2021 to 2026 (USD Million)
  155. Middle East & Africa Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  156. Middle East & Africa Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  157. Middle East & Africa Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  158. Middle East & Africa Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  159. Middle East & Africa Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  160. Middle East & Africa Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  161. Middle East & Africa Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  162. Middle East & Africa Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  163. Middle East & Africa Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  164. Middle East Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  165. Middle East Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  166. Middle East Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  167. Africa Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  168. Africa Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  169. Africa Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample